p33monox Antibody

What is p33MONOX and why is it significant in research?

p33MONOX (also known as KIAA1191, Brain-derived rescue factor p60MONOX, or hypothetical protein LOC57179) is a protein of significant interest in human cellular research. The p33MONOX antibody is a rabbit polyclonal antibody specifically designed to detect this protein in human samples. The significance of p33MONOX lies in its expression patterns in human tissues, particularly in the brain, making it valuable for neurological research. The antibody enables researchers to visualize and quantify the presence of this protein through various immunological techniques, contributing to our understanding of its biological functions and potential role in disease mechanisms .

What are the validated applications for p33MONOX antibody?

The p33MONOX polyclonal antibody has been validated for several key immunological applications essential for research. These include immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), and immunohistochemistry on paraffin-embedded tissues (IHC-P). Each of these applications has specific working dilutions: for IHC and IHC-P, the recommended dilution range is 1:500-1:1000, while for ICC/IF, the optimal concentration is 1-4 μg/mL. These applications allow researchers to visualize p33MONOX in various experimental contexts, from fixed tissue sections to cultured cells, providing flexibility in experimental design .

How does antibody specificity influence experimental outcomes when using p33MONOX antibody?

Antibody specificity is crucial for reliable experimental outcomes. The p33MONOX antibody's specificity has been verified using a Protein Array containing the target protein plus 383 other non-specific proteins, confirming its selective binding capabilities . This high specificity reduces background signal and false positives in experiments. Drawing parallels from research on antibody specificity, we understand that even minor differences in binding profiles can significantly impact experimental outcomes . For accurate results, researchers should validate the specificity of their p33MONOX antibody lot before conducting critical experiments, particularly when working with complex tissue samples where cross-reactivity might occur.

What are the recommended controls when using p33MONOX antibody in immunohistochemistry?

When conducting immunohistochemistry with p33MONOX antibody, several controls are essential to ensure reliable and interpretable results. Based on standard immunohistochemical practices, researchers should implement:

• Positive control: Human tissue samples known to express p33MONOX, particularly brain tissue where this protein has been documented.

• Negative control: Omission of primary antibody while maintaining all other steps in the protocol.

• Isotype control: Using a non-specific rabbit IgG at the same concentration as the p33MONOX antibody.

• Absorption control: Pre-incubating the antibody with its immunizing peptide to confirm specificity.

• Tissue controls: Including tissues known not to express p33MONOX to validate specificity.

These controls help distinguish between specific staining and background or non-specific binding, which is particularly important when working with polyclonal antibodies that may contain a heterogeneous mixture of immunoglobulins with varying affinities .

How can researchers optimize p33MONOX antibody detection in samples with low protein expression?

Optimizing detection of p33MONOX in samples with low protein expression requires a multi-faceted approach:

• Signal amplification systems: Implement tyramide signal amplification (TSA) or polymer-based detection systems that provide significantly higher sensitivity than conventional methods.

• Antigen retrieval optimization: Systematically test different antigen retrieval methods (heat-induced vs. enzymatic) and conditions (buffer composition, pH, duration, temperature) to maximize epitope accessibility.

• Concentration adjustment: Increase antibody concentration gradually from the recommended 1:500 dilution to as high as 1:100, while carefully monitoring background signals.

• Extended incubation: Employ longer primary antibody incubation times (overnight at 4°C) to enhance binding to sparse antigens.

• Reduce background: Implement additional blocking steps with 5-10% normal serum matched to the host of the secondary antibody, plus 0.1-0.3% Triton X-100 to reduce non-specific binding.

Each optimization step should be systematically documented and evaluated for signal-to-noise ratio to determine the optimal protocol for specific sample types .

What experimental approaches can resolve contradictory results when using p33MONOX antibody across different detection platforms?

When contradictory results arise across different detection platforms using p33MONOX antibody, a systematic troubleshooting approach is necessary:

• Orthogonal validation: Confirm protein expression using independent methods such as RT-PCR for mRNA or mass spectrometry for protein.

• Epitope mapping analysis: Determine if different fixation or preparation methods might affect the accessibility of the epitope recognized by the antibody.

• Correlation analysis: Perform correlation studies between results from different detection methods to identify patterns in discrepancies.

• Binding mode characterization: Following approaches similar to those described for other antibodies , characterize the binding modes of p33MONOX antibody under different experimental conditions.

• Sequential dilution series: Create a standard curve across multiple platforms to determine if discrepancies are concentration-dependent.

These approaches help researchers distinguish between true biological variations and technical artifacts, allowing for more accurate interpretation of experimental results when using the p33MONOX antibody .

What is the optimal protocol for using p33MONOX antibody in immunofluorescence studies?

The optimal protocol for p33MONOX antibody in immunofluorescence studies involves several critical steps and considerations:

Materials:

• p33MONOX antibody (1-4 μg/mL final concentration)

• Appropriate secondary antibody (anti-rabbit IgG with fluorescent conjugate)

• Blocking solution (5% normal goat serum in PBS)

• PBS with 0.1% Tween-20 (PBST)

• 4% paraformaldehyde

• 0.1% Triton X-100

• Mounting medium with DAPI

Protocol:

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature.

• Wash three times with PBS (5 minutes each).

• Permeabilize with 0.1% Triton X-100 in PBS for 10 minutes.

• Wash three times with PBS (5 minutes each).

• Block with 5% normal goat serum in PBS for 1 hour at room temperature.

• Incubate with p33MONOX antibody diluted to 2 μg/mL in blocking solution overnight at 4°C.

• Wash three times with PBST (10 minutes each).

• Incubate with fluorophore-conjugated secondary antibody (1:500) for 1 hour at room temperature in the dark.

• Wash three times with PBST (10 minutes each).

• Mount with medium containing DAPI.

• Image using appropriate fluorescence microscopy.

This protocol has been optimized based on the antibody specifications and general principles of immunofluorescence techniques. The extended primary antibody incubation significantly improves signal detection while maintaining specificity .

How should researchers prepare and store the p33MONOX antibody to maintain its activity?

Proper handling and storage of p33MONOX antibody is crucial for maintaining its activity and ensuring consistent experimental results:

Initial Preparation:

• Upon receipt, briefly centrifuge the antibody vial before opening to collect the liquid at the bottom.

• For long-term storage, divide the antibody into small aliquots (5-10 μL) in sterile microcentrifuge tubes.

• Avoid repeated freeze-thaw cycles that can denature antibodies and reduce their activity.

Storage Conditions:

• Short-term storage (up to 2 weeks): 4°C

• Long-term storage: -20°C in aliquots

• Avoid storing at -80°C as this can be detrimental to antibody structure

Working Solution Preparation:

• Thaw aliquots at room temperature or on ice.

• Prepare working dilutions fresh on the day of the experiment.

• Dilute in appropriate buffer containing 1% BSA or 5% normal serum as a carrier protein.

• Discard unused diluted antibody after the experiment.

Stability Considerations:

• Track the number of freeze-thaw cycles for each aliquot.

• Validate antibody activity after extended storage periods using positive controls.

• Consider adding sodium azide (0.02%) as a preservative for long-term storage, noting that this may interfere with some applications like cell culture .

What quantitative methods are recommended for analyzing p33MONOX expression data from immunohistochemistry?

For rigorous quantitative analysis of p33MONOX expression in immunohistochemistry:

Digital Image Analysis Methods:

• H-score method: Calculate using the formula: H-score = (1 × % cells with weak intensity) + (2 × % cells with moderate intensity) + (3 × % cells with strong intensity)

• Immunoreactive Score (IRS): Multiply staining intensity (0-3) by percentage of positive cells (0-4) to obtain scores ranging from 0-12.

• Automated image analysis: Use software like ImageJ with color deconvolution to separate and quantify DAB staining.

Statistical Analysis Recommendations:

• For comparing expression between groups, use non-parametric tests (Mann-Whitney U or Kruskal-Wallis) as immunohistochemistry data often does not follow normal distribution.

• For correlation with clinical parameters, apply Spearman's rank correlation coefficient.

Standardization Practices:

• Include standard reference samples in each batch of staining.

• Normalize expression data against housekeeping proteins.

• Use tissue microarrays when possible to minimize technical variation.

Reproducibility Measures:

• Have multiple trained observers score samples independently.

• Calculate inter-observer and intra-observer correlation coefficients.

• Use digital pathology tools for more objective assessment.

These methods allow for reliable quantification of p33MONOX expression patterns, enabling statistical comparisons between experimental groups while minimizing subjective interpretation biases .

How does the binding affinity of p33MONOX antibody compare with other polyclonal antibodies targeting similar proteins?

While specific binding affinity data (KD values) for p33MONOX antibody is not directly available in the provided literature, we can make informed comparisons based on general principles and similar antibodies. Drawing from comparative binding affinity studies of other polyclonal antibodies, we can establish a framework for understanding the relative binding characteristics:

For context, the monoclonal antibodies described in source demonstrated KD values of 9.4 × 10^-10 M (mAb-4G3), 4.3 × 10^-9 M (mAb-5G2), and 2.4 × 10^-9 M (mAb-9H2), showing the range of binding affinities typical for highly specific antibodies .

The p33MONOX polyclonal antibody likely exhibits binding affinities in the nanomolar range, which is sufficiently strong for most research applications while maintaining the advantage of recognizing multiple epitopes on the target protein. This multi-epitope recognition can be particularly advantageous when protein conformations might vary across different experimental conditions or sample preparations .

What are the emerging applications of p33MONOX antibody in neurodegenerative disease research?

The p33MONOX antibody has emerging potential in neurodegenerative disease research, particularly due to the expression patterns of its target protein in brain tissue. While specific studies on p33MONOX in neurodegeneration aren't detailed in the provided sources, we can extrapolate from similar research frameworks:

• Biomarker Development: The antibody can be utilized to evaluate p33MONOX expression patterns in normal versus diseased brain tissue, potentially establishing it as a diagnostic or prognostic biomarker.

• Pathological Mechanism Investigation: By visualizing p33MONOX localization and quantifying expression changes during disease progression, researchers can investigate its potential role in pathological processes.

• Drug Target Validation: If p33MONOX is implicated in disease mechanisms, the antibody becomes valuable for validating this protein as a therapeutic target and for screening compound libraries that modulate its function.

• Cellular Stress Response Studies: Drawing parallels with proteins like ASK1 (described in source ), which plays crucial roles in cellular stress responses, p33MONOX might similarly be involved in neuronal stress pathways relevant to neurodegeneration.

• Protein Interaction Network Mapping: The antibody can be employed in co-immunoprecipitation studies to identify interaction partners of p33MONOX, potentially revealing new disease-relevant pathways.

These emerging applications highlight how the p33MONOX antibody could contribute to advancing our understanding of neurodegenerative mechanisms and potentially lead to new therapeutic strategies .

How can computational modeling enhance p33MONOX antibody specificity and cross-reactivity profiles for advanced research applications?

Computational modeling approaches can significantly enhance our understanding and optimization of p33MONOX antibody specificity, drawing from advanced antibody engineering principles detailed in source :

• Epitope Mapping and Refinement: Computational analysis of the p33MONOX protein sequence can identify immunogenic epitopes and predict antibody binding sites, guiding the development of more specific variants.

• Biophysics-Informed Modeling: As described in , biophysical models learned from selections against multiple ligands can be applied to design antibodies with tailored specificity profiles:

  • Identify distinct binding modes associated with specific epitopes

  • Predict cross-reactivity with similar proteins

  • Generate variants with enhanced specificity for p33MONOX

• Machine Learning Integration: Training models on experimental data from phage display experiments (similar to those described in ) can:

  • Predict binding affinities for novel antibody sequences

  • Identify key residues that contribute to specificity

  • Design modifications to reduce off-target binding

• Molecular Dynamics Simulations: These can model the dynamic interactions between p33MONOX antibody and its target, revealing:

  • Conformational changes upon binding

  • Energetic contributions to binding specificity

  • Potential for allosteric effects

• Tailored Specificity Design: Using approaches outlined in , researchers could design p33MONOX antibody variants with:

  • Enhanced specificity for particular epitopes

  • Reduced cross-reactivity with similar proteins

  • Customized binding profiles for specific experimental needs

This computational enhancement of antibody properties represents the cutting edge of antibody research, allowing for rational design rather than relying solely on empirical selection methods .

What multiplexing strategies are most effective when using p33MONOX antibody alongside other markers?

Effective multiplexing with p33MONOX antibody requires careful consideration of several technical factors:

Validated Multiplexing Approaches:

• Sequential Immunofluorescence Staining:

  • Begin with the lowest abundance target (often p33MONOX)

  • Use primary antibodies from different host species (p33MONOX is rabbit-derived)

  • Employ spectrally distinct fluorophores (minimum 30nm separation between emission peaks)

  • Include stringent washing steps between antibody applications

• Chromogenic Multiplexing:

  • Sequential application with complete chromogen development and antibody stripping

  • Use different chromogens (DAB, AEC, Fast Red) for distinct visualization

  • Carefully optimize antibody dilutions to achieve balanced signal intensity

• Tyramide Signal Amplification (TSA) Multiplexing:

  • Allows use of multiple rabbit antibodies through sequential staining and heat-mediated antibody removal

  • Particularly useful when combining p33MONOX with other rabbit-derived antibodies

  • Requires precise microwave treatment conditions between rounds (96°C for 10 minutes in citrate buffer)

Optimization Parameters for Successful Multiplexing:

These approaches enable simultaneous visualization of p33MONOX alongside other cellular markers, providing valuable contextual information about its localization and co-expression patterns .

How can researchers validate and troubleshoot unexpected p33MONOX antibody staining patterns?

When faced with unexpected staining patterns using p33MONOX antibody, a systematic validation and troubleshooting approach is essential:

Validation Strategy:

• Confirmatory Approaches:

  • Employ multiple antibodies targeting different epitopes of p33MONOX

  • Validate with orthogonal methods (mRNA detection, mass spectrometry)

  • Perform siRNA knockdown of p33MONOX to confirm staining specificity

  • Compare staining patterns across multiple tissue or cell types

• Technical Controls:

  • Test antibody performance on known positive and negative control samples

  • Perform peptide competition assays with the immunizing peptide

  • Examine the effect of different fixation methods on staining patterns

  • Evaluate staining in tissues from different species to assess cross-reactivity

Troubleshooting Decision Tree:

For nuclear staining when cytoplasmic is expected:

• Verify subcellular localization data from protein databases

• Test different fixation protocols (aldehyde vs. alcohol-based)

• Evaluate whether specific stimuli might trigger nuclear translocation

For diffuse staining instead of expected discrete patterns:

• Optimize fixation duration (overfixation can mask epitopes)

• Try different antigen retrieval methods (pH 6 vs. pH 9 buffers)

• Reduce antibody concentration to improve signal-to-noise ratio

• Consider detergent concentration adjustments to control membrane permeabilization

For high background or non-specific staining:

• Increase blocking time and concentration (try 10% serum for 2 hours)

• Include additional blocking agents (0.1-0.3% Triton X-100, 0.05% Tween-20)

• Perform additional washing steps with increased stringency

• Optimize secondary antibody dilution and incubation time

This systematic approach allows researchers to distinguish between true biological findings and technical artifacts when unexpected staining patterns emerge .

What are the considerations for using p33MONOX antibody in super-resolution microscopy studies?

Super-resolution microscopy with p33MONOX antibody requires specific adaptations to standard protocols:

Technical Requirements and Optimizations:

• Fluorophore Selection:

  • For STED microscopy: Use ATTO647N or Abberior STAR RED conjugated secondary antibodies

  • For STORM/PALM: Alexa Fluor 647 provides optimal photoswitching properties

  • For SIM: Alexa Fluor 488 or 568 offer superior photostability

• Sample Preparation Considerations:

  • Use thinner sections (≤5μm) for tissue samples to reduce out-of-focus signal

  • Mount samples in specialized media with matched refractive index

  • For STORM: Use oxygen scavenging buffer systems containing glucose oxidase/catalase

  • Optimize fixation to preserve nanoscale structures (4% PFA + 0.2% glutaraldehyde recommended)

• Antibody Concentration Adjustments:

  • Increase primary antibody concentration to 4-8 μg/mL (higher than standard IF)

  • Extend incubation time to 24-48 hours at 4°C for improved penetration

  • Consider using Fab fragments as secondary reagents to minimize linkage error

• Validation Controls:

  • Perform correlative conventional and super-resolution imaging

  • Include fiducial markers for drift correction

  • Use multicolor imaging with known markers to validate localization patterns

• Data Analysis Considerations:

  • Apply appropriate filtering algorithms to remove localization uncertainty

  • Use cluster analysis to quantify nanoscale distribution patterns

  • Implement coordinate-based colocalization analysis for multi-protein studies

These specialized approaches allow researchers to visualize p33MONOX distribution at nanoscale resolution, potentially revealing previously undetectable protein organization patterns and interactions .

How can researchers design experiments to study the dynamic regulation of p33MONOX using the antibody in live cell imaging?

Designing experiments for studying dynamic regulation of p33MONOX in live cells presents unique challenges, requiring adaptations of conventional antibody techniques:

Experimental Design Strategies:

• Generation of Fusion Constructs:

  • Create p33MONOX-GFP/RFP fusion proteins for direct visualization

  • Validate fusion protein functionality compared to endogenous protein

  • Develop cell lines with stable, inducible expression

  • Use p33MONOX antibody in fixed cells to validate fusion protein localization patterns

• Antibody Fragment-Based Approaches:

  • Develop Fab fragments from the p33MONOX antibody

  • Conjugate fragments with cell-permeable fluorophores

  • Validate entry and binding specificity in fixed cells first

  • Optimize concentration to minimize interference with protein function

• CRISPR-Based Tagging:

  • Use CRISPR/Cas9 to insert small epitope tags into the endogenous p33MONOX gene

  • Apply fluorescently-labeled nanobodies against the tag for visualization

  • Validate tag insertion and expression with p33MONOX antibody in fixed cells

  • Assess impact on protein function through comparative assays

• Experimental Parameters for Dynamic Studies:

• Validation Approach:

  • Confirm key findings in fixed cells using conventional p33MONOX antibody staining

  • Correlate live cell observations with biochemical assays

  • Use pharmacological perturbations to confirm regulatory mechanisms

  • Perform parallel experiments with mutant variants to identify regulatory domains

These approaches enable researchers to bridge static antibody-based observations with dynamic protein regulation studies, providing insights into the temporal aspects of p33MONOX function .